-- 大手油田サービス会社ハリバートン(HAL)は、北米のシェールオイル開発活動に回復の「初期兆候」が見られると発表しました。水圧破砕市場の供給逼迫は、需要状況の改善を示唆しています。 火曜日に開催された2026年第1四半期決算説明会で、ジェフリー・アレン・ミラー社長兼CEOは、年初数ヶ月間は「空白期間」があった水圧破砕スケジュールが、業界全体の需要急増を受けて、現在では埋まっていると述べました。 ミラー氏は、年初には完成作業の減少や遅延を懸念していたものの、「もはや懸念材料ではない」と述べました。 同社はまた、特に小規模事業者からのスポット作業依頼の増加を、需要増加の初期兆候として挙げました。 ハリバートンのシャノン・スロカムCOOは、まだ「初期段階」ではあるものの、「北米の状況は建設的だ」との見解を示しました。同社はまた、高級機器市場は既に逼迫しており、業界全体がほぼ完売状態まであと「ほんの数台の車両」しかないと付け加えた。 しかしながら、経営陣は市場シェアの獲得よりも収益の最大化に引き続き注力し、既存車両の価格設定と活用を優先すると述べた。
Related Articles
Scotiabank Previews This Week's February and Preliminary March GDP for Canada
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%